This week, we will discuss the final results of the NEFIGARD trial with the GFR slope data. Is targeted release budesonide aka Nefecon really a way to provide steroid efficacy without steroid side effects?
This week, we tag along with NephMadness. It will be hard to stay impartial while discussing the role of angiogenic and antiangiogenic factors in severe preeclampsia prognosis.
This week, during kidney month and NephMadness season, we will discuss the USRDS report as well as the ISN Global Kidney Health Atlas report from 2024.
This week, we will discuss the hot off the press. On the quest to solve the disparity created by GFR calculations, we discuss the new equations. Is it time to drop the race coefficient, or is it time to drop serum creatinine entirely?
This week, we will discuss a pilot trial of using mannitol to treat intradialytic hypotension. A daily occurence in our practice, hence providing some much needed data.